Pneumonia, an inflammatory condition of the lung usually due to bacterial and/or viral infection, is the third leading cause of death worldwide and a major cause of morbidity and mortality in children, adults and the elderly.

Bacterial pneumonia and the growing threat of antimicrobial resistance (AMR) are major public health concerns across Europe and new alternative strategies must be developed to address these issues.

FAIR will combine MultiOmics and computational biology to define the contribution of flagellin towards protection and the downstream immune effectors responsible for the gain of protection during combination therapy.

FAIR will not only benefit from an existing pneumonia patient cohort (MARS), but will also establish a new cohort (BIO-PNEU), a first-in-man Phase I clinical trial (NEBUFLAG) and a socio-economic study on patients, volunteers and healthcare professionals (ADVIFLAG).

NEBUFLAG – A first-in-man phase 1 trial for nebulization of flagellin to treat respiratory infections.